BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/14/2018 5:53:04 AM | Browse: 1095 | Download: 1478
 |
Received |
|
2018-04-27 09:00 |
|
Peer-Review Started |
|
2018-04-27 09:45 |
|
To Make the First Decision |
|
2018-05-30 00:21 |
|
Return for Revision |
|
2018-06-11 08:51 |
|
Revised |
|
2018-06-25 12:11 |
|
Second Decision |
|
2018-07-13 07:25 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-07-16 01:51 |
|
Articles in Press |
|
2018-07-16 01:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2018-07-21 23:11 |
|
Typeset the Manuscript |
|
2018-09-05 07:27 |
|
Publish the Manuscript Online |
|
2018-09-14 05:53 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Drug resistance and new therapies in colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kevin Van der Jeught, Han-Chen Xu, Yu-Jing Li, Xiong-Bin Lu and Guang Ji |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| NSFC |
81620108030 |
| NIH |
CA203737 |
|
| Corresponding Author |
Guang Ji, MD, PhD, Chief Doctor, Professor, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Shanghai 200032, China. jiliver@vip.sina.com |
| Key Words |
Colorectal cancer; Therapy resistance; Antibody-drug conjugates; α-amanitin; Tumor microenvironment; Immunotherapy; Checkpoint inhibitors; Microbiome |
| Core Tip |
Therapy resistance has been a culprit for colorectal cancer (CRC) treatment. Here, we review a novel therapeutic approach using α-amanitin antibody-drug conjugates inhibiting RNA polymerase Ⅱ against CRC with hemizygous loss of p53. Since its mechanism of cell killing is independent of the generally used tubulin inhibitors and chemotherapy drugs, this approach shows the promise to overcome common drug resistance. In addition, we summarize the sensitivity of CRC to newly developed immune checkpoint inhibitors. While patients with microsatellite instability-high CRC remain the sole subgroup responsive to current checkpoint inhibitors so far, we highlight potentially new developments that may lead to promising results in treating patients with microsatellite-stable CRC, which constitutes the majority of this disease. |
| Publish Date |
2018-09-14 05:53 |
| Citation |
Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24(34): 3834-3848 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i34/3834.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i34.3834 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
